Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Lindera obtusiloba extract

A dietary supplement composed of an ethanol extracted powder of Lindera obtusiloba, with potential antioxidant and anti-inflammatory activities. Upon administration, Lindera obtusiloba extract (LOE) may promote anti-oxidant activities through the activation of nuclear factor erythroid 2-related factor 2 (Nrf-2)/heme oxygenase 1 (HO-1)/ NAD(P)H dehydrogenase [quinone] 1 (NQO1), which reduces the production of reactive oxygen species (ROS) and lowers ROS-mediated oxidative stress. In addition, LOE may exert anti-inflammatory effects through the inhibition of the phosphorylation and activation of mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-kB).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:L. obtusiloba extract
Abbreviation:LOE
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search